Whether proTα or proTα(100–109), in synergy with GM-CSF or combined with one or more TLR agonists [42,43] or other immunoregulatory strategies (e.g., checkpoint blockade) [44,45], could generate higher levels of tumor-specific Th1 cells with active immunization, remains to be tested. Here, CSF2 is linked to neoplasm.